Consolidated Balance Sheets (USD $)	Dec. 31, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 16,455,995	$ 9,748,491
Prepaid research and development	1,990,759
Other current assets	29,128	87,176
Total current assets	18,475,882	9,835,667
Equipment, net	1,164	0
In-process research and development	2,797,600	3,902,300
Goodwill	799,391	799,391
Total assets	22,074,037	14,537,358
Liabilities and equity
Notes payable, current portion	677,778	877,778
Accounts payable and accrued expenses	1,117,397	666,640
Accrued compensation	145,000	0
Current portion of deferred revenue	152,381	0
Interest payable, current portion	123,511	61,941
Total current liabilities	2,216,067	1,606,359
Deferred revenue, net of current portion	1,828,571	0
Notes payable, less current portion, at fair value	2,479,098	3,294,797
Total liabilities	6,523,736	4,901,156
Commitments and contingencies
Equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 and 413,388 issued and outstanding as of December 31, 2012 and 2011, respectively, aggregate liquidation value of $0 and $8,267,760 at December 31, 2012 and 2011, respectively)	0	413
Common stock, $0.001 par value per share (500,000,000 shares authorized, 25,820,738 and 5,061,399 shares issued and outstanding at December 31, 2012 and 2011, respectively)	25,821	5,061
Contingently issuable shares	6	6
Additional paid-in capital	34,534,805	10,472,115
Treasury stock, at cost, 13,526 and 0 shares at December 31, 2012 and 2011, respectively	(84,538)	0
Deficit accumulated in the development stage	(18,925,793)	(853,074)
Total stockholder's equity	15,550,301	9,624,521
Non-controlling interest in subsidiary	0	11,681
Total equity	15,550,301	9,636,202
Total liabilities and equity	$ 22,074,037	$ 14,537,358